GSK: US patient withdraws in Zantac case

(CercleFinance.com) - GSK said on Friday that a US patient has dropped his lawsuit against the company in the dispute over the heartburn drug Zantac.


The biopharmaceutical giant said that Joseph Bayer's lawyer, whose case was to be the first to be heard at trial, informed the court yesterday of his intention to file a notice of voluntary dismissal.

The group simply says it welcomes this development, which it considers logical given the nature of the case.

The overwhelming weight of scientific evidence supports the conclusion that there is no increased risk of cancer associated with the use of ranitidine, it said.

Several pharmaceutical companies, including GSK and Sanofi, are currently facing complaints from consumers who suspect that Zantac, a treatment for stomach acidity marketed until 2019 in the US, contains a potentially carcinogenic compound.

GSK says it will continue to defend itself "vigorously" against any such claims.

To date, the company says it is aware of some 3,000 claims against it for compensation for personal injury.

On the London Stock Exchange, GSK shares were down 1.3% on Wednesday morning following the news.


Copyright (c) 2022 CercleFinance.com. All rights reserved.